I. B. Pedersen, N. Knudsen, H. Perrild, L. Ovesen and P. Laurberg, “TSH-Receptor Antibody Measurement for Differentiation of Hyperthyroidism into Graves’ Disease and Multinodular Toxic Goitre: A Comparison of Two Competitive Binding Assays,” Clinical Endocrinology (Oxf), Vol. 55, No. 3, 2001, pp. 381-390.
http://dx.doi.org/10.1046/j.1365-2265.2001.01347.x

has been cited by the following article:

• TITLE: Grave’s Eye Ophthalmopathy Developing Following Radioiodine Therapy for Toxic Adenoma

  AUTHORS: Hala Chafic Ahmadieh, Ibrahim Salti

  KEYWORDS: Grave’s Ophthalmopathy; Toxic Adenoma; Toxic Nodular Goiter; Radioiodine Therapy

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.3 No.6, October 24, 2013

  ABSTRACT: The development of Grave’s ophthalmopathy following radioiodine treatment for Grave’s disease is well recognized. However, development of Grave’s ophthalmopathy following radioiodine therapy given for toxic adenoma or toxic nodular goiter has been reported but very rarely. Hereby, we reported a case of a 69-year-old male patient who developed ophthalmopathy after receiving 30 mCi (1110 mBq) 131 I radioiodine treatment for a toxic nodule. In addition, a review of the current literature with regards to this topic is presented.